News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
U.S. Panel Backs Dendreon Corporation’s Provenge for Medicare
November 18, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON (Reuters) - A U.S. advisory panel backed Dendreon Corp's Provenge prostate cancer therapy on Wednesday, telling the Medicare insurance program for the elderly that available data showed it could help patients.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
Drug pricing
In Affordability Push, EMD Serono Joins TrumpRx While Roche Launches DTC Program
October 17, 2025
·
2 min read
·
Tristan Manalac
Government
FDA’s Orphan Drug Director Out Amid IRA Exemption Rollout
October 16, 2025
·
2 min read
·
Tristan Manalac
Government
Chaos at CDC Continues as Hundreds Fired, Rehired
October 13, 2025
·
2 min read
·
Tristan Manalac
BIOSECURE Act
The BIOSECURE Act Is Back, as Congress Tacks New Version On to Broader Defense Bill
October 10, 2025
·
1 min read
·
Annalee Armstrong